22.418 articles found

Treatment of early Parkinson's disease. Part 2.

Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.

Eur Neurol · 2009-01-29

DOI: 10.1159/000197104PMID: 19176961

SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA

FAYOL AUDE, LOCHEAD ALISTAIR, SAADY MOURAD, VACHE JULIEN, YAICHE PHILIPPE.

· 2009-01-27

A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency.

Allen GF, Land JM, Heales SJ.

Mol Genet Metab · 2009-01-27

DOI: 10.1016/j.ymgme.2009.01.010PMID: 19231266

Pharmacotherapy of Parkinson disease dementia and Lewy body dementia.

Gauthier S.

Front Neurol Neurosci · 2009-01-26

DOI: 10.1159/000197892PMID: 19182471

Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy.

Crittenden JR, Cantuti-Castelvetri I, Saka E, Keller-McGandy CE, Hernandez LF, Kett LR, Young AB, Standaert DG, Graybiel AM.

Proc Natl Acad Sci U S A · 2009-01-26

DOI: 10.1073/pnas.0812822106PMID: 19171906

THE USE OF GLYCOSYLATED ANTITUMOR ETHER LIPIDS TO INDUCE AND/OR ENHANCE AUTOPHAGY FOR TREATMENT OF DISEASES

ARTHUR GILBERT, BITTMAN ROBERT.

· 2009-01-23

Exercise therapy for prevention of falls in people with Parkinson's disease: a protocol for a randomised controlled trial and economic evaluation.

Canning CG, Sherrington C, Lord SR, Fung VS, Close JC, Latt MD, Howard K, Allen NE, O'Rourke SD, Murray SM.

BMC Neurol · 2009-01-22

DOI: 10.1186/1471-2377-9-4PMID: 19161631

Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study.

Sossi V, Dinelle K, Topping GJ, Holden JE, Doudet D, Schulzer M, Ruth TJ, Stoessl AJ, de la Fuente-Fernandez R.

J Neurochem · 2009-01-22

DOI: 10.1111/j.1471-4159.2009.05904.xPMID: 19183257

Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Marin C, Aguilar E, Rodríguez-Oroz MC, Bartoszyk GD, Obeso JA.

Psychopharmacology (Berl) · 2009-01-22

DOI: 10.1007/s00213-008-1452-9PMID: 19159919

Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.

Talati R, Reinhart K, Baker W, White CM, Coleman CI.

Parkinsonism Relat Disord · 2009-01-22

DOI: 10.1016/j.parkreldis.2008.12.007PMID: 19167259

Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics.

Lin L, Lesnick TG, Maraganore DM, Isacson O.

Trends Neurosci · 2009-01-21

DOI: 10.1016/j.tins.2008.11.006PMID: 19162339

Serpentine tongue: A rare manifestation following initiation of levodopa therapy in a patient with Parkinson's disease.

Prashantha DK, Pal PK.

Parkinsonism Relat Disord · 2009-01-21

DOI: 10.1016/j.parkreldis.2008.12.004PMID: 19157953